Cookie Einstellungen
Diese Webseite verwendet ausschließlich notwendige Cookies, die für die Funktion erforderlich sind. Marketing- und Statistik-Cookies kommen nicht zum Einsatz. Weitere Informationen finden Sie in unserer Datenschutzerklärung.
 Notwendig   Details einblenden
      OK      
Bitte logge Dich ein, um diese Funktion zu nutzen!
      OK      
x
Impact News +++ Navan (NAVN) Sued Over IPO Disclosures; Investors Face April 24 Deadline - Hagens Berman (PR Newswire) +++ NAVAN Aktie -4,27%

KIORA PHARMACEUTICALS Aktie

>KIORA PHARMA Performance
1 Woche: 0%
1 Monat: 0%
3 Monate: 0%
6 Monate: 0%
1 Jahr: 0%
laufendes Jahr: 0%
>KIORA PHARMACEUTICALS Aktie
Name:  KIORA PHARMACEUTICALS
Land:  USA
Sektor:  Gesundheit
ISIN/ Wkn:  US49721T5074 / A40EG5
Symbol/ Ticker:  7EY (Frankfurt) / KPRX (NASDAQ)
Kürzel:  FRA:7EY, ETR:7EY, 7EY:GR, NASDAQ:KPRX
Index:  -
Webseite:  https://kiorapharma.com/
Profil:  -
Marktkapitalisierung:  6.59 Mio. EUR
Unternehmenswert:  -7.86 Mio. EUR
Umsatz:  -
EBITDA:  -8.09 Mio. EUR
Nettogewinn:  -9.37 Mio. EUR
Gewinn je Aktie:  -2.41 EUR
Schulden:  0.32 Mio. EUR
Liquide Mittel:  7.52 Mio. EUR
Operativer Cashflow:  -8.61 Mio. EUR
Bargeldquote:  4.71
Umsatzwachstum:  -100%
Gewinnwachstum:  -401.42%
Dividende je Aktie:  -
Dividendenrendite:  -
Dividendenschätzung:  -
Insiderhandel:  -
Suchwörter:  KIORA PHARMACEUTICALS, KIORA PHARMA, KIORA PHARMACEUTICAL
Letzte Datenerhebung:  01.04.26
>KIORA PHARMA Kennzahlen
Aktien/ Unternehmen:
Aktien: 3.95 Mio. St.
Frei handelbar: 91.28%
Rückkaufquote: -3.48%
Mitarbeiter: 13
Umsatz/Mitarb.: -
Analysten:
Analystenrating: Strong buy
Kursziel: 521.76%
Bewertung:
KGV: -
KGV lG: -
KUV: -
KBV: 0.45
PEG-Ratio: -
EV/EBITDA: -
Rentabilität:
Bruttomarge: -
Gewinnmarge: -
Operative Marge: -
Managementeffizenz:
Gesamtkaprendite: -35.68%
Eigenkaprendite: -51.74%
>KIORA PHARMA Peer Group
Gesundheit
 
25.03.26 - 12:15
Kiora Pharmaceuticals GAAP EPS of -$2.64 (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
25.03.26 - 12:06
Kiora Pharmaceuticals, Inc.: Kiora Pharmaceuticals Reports Fourth-Quarter and Full-Year 2025 Results; Company Advances Retinal Disease Pipeline with Two Active Phase 2 Clinical Trials (Newsfile)
 
Encinitas, California--(Newsfile Corp. - March 25, 2026) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") today announced financial results for the fourth quarter and full y......
19.02.26 - 14:48
Kiora Pharmaceuticals, Inc.: Kiora Pharmaceuticals to Present at Oppenheimer′s 36th Annual Healthcare Life Sciences Conference (Newsfile)
 
Encinitas, California--(Newsfile Corp. - February 19, 2026) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) today announced that the company will present at the Oppenheimer 36th Annual Healthcare Lif......
01.12.25 - 12:54
Kiora Pharmaceuticals, Inc.: Kiora Pharmaceuticals Granted U.S. Patent Covering Additional Formulations for the KIO-100 Family of Anti-Inflammatory Compounds (Newsfile)
 
Encinitas, California--(Newsfile Corp. - December 1, 2025) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) today announced that the U.S. Patent and Trademark Office issued a new patent (US-12,472,263......
07.11.25 - 12:33
Kiora Pharmaceuticals GAAP EPS of $0.01 beats by $0.74 (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
07.11.25 - 12:06
Kiora Pharmaceuticals, Inc.: Kiora Pharmaceuticals Reports Third Quarter 2025 Results; Company Advances Pipeline with Two Actively Enrolling Phase 2 Clinical Trials for Retinal Diseases (Newsfile)
 
Encinitas, California--(Newsfile Corp. - November 7, 2025) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") today announced third quarter 2025 financial results and provided......
30.10.25 - 14:03
Kiora Pharmaceuticals Joins RARE-X Vision Consortium Promoting Collaboration and Development of New Treatments for Rare Ocular Disorders (PR Newswire)
 
ENCINITAS, Calif. and WASHINGTON D.C., Oct. 30, 2025 /PRNewswire/ -- Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) and Global Genes today announced that Kiora has joined Global Genes' RARE-X Vision Consortium, a corporate-nonprofit partnership with a mission to promote and facilitate......
15.10.25 - 13:06
Kiora Pharmaceuticals, Inc.: Kiora Pharmaceuticals to Participate in the 2025 Maxim Growth Summit and Eyecelerator @ AAO 2025 (Newsfile)
 
Encinitas, California--(Newsfile Corp. - October 15, 2025) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) today announced that it will participate in an ophthalmology panel at the upcoming 2025 Maxi......
04.09.25 - 13:12
Kiora Pharmaceuticals, Inc.: Kiora Pharmaceuticals to Webcast On-Demand Presentation at The H.C. Wainwright 27th Annual Global Investment Conference (Newsfile)
 
Encinitas, California--(Newsfile Corp. - September 4, 2025) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) today announced that its Chief Financial Officer, Melissa Tosca, CPA, will showcase the Com......
08.08.25 - 13:12
Kiora Pharmaceuticals GAAP EPS of -$0.54 (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
08.08.25 - 13:06
Kiora Pharmaceuticals, Inc.: Kiora Pharmaceuticals Reports Second Quarter 2025 Results; Company Advances Pipeline with Two Active Phase 2 Clinical Trials for Retinal Diseases (Newsfile)
 
Encinitas, California--(Newsfile Corp. - August 8, 2025) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") today announced second quarter 2025 financial results and provided ......
07.08.25 - 13:24
Kiora Pharmaceuticals, Inc.: Kiora Pharmaceuticals to Showcase Its Retinal Disease Therapeutic Pipeline at The H.C. Wainwright 5th Annual Ophthalmology Virtual Conference (Newsfile)
 
Encinitas, California--(Newsfile Corp. - August 7, 2025) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) today announced that its President and CEO, Brian M. Strem, Ph.D., will showcase the Company's......
22.07.25 - 15:21
Kiora Pharmaceuticals granted U.S. patent expanding protection for KIO-104 for treatment of ocular disease (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
22.07.25 - 15:06
Kiora Pharmaceuticals, Inc.: Kiora Pharmaceuticals Granted U.S. Patent Expanding Protection for KIO-104 in the Treatment of Ocular Disease (Newsfile)
 
Encinitas, California--(Newsfile Corp. - July 22, 2025) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) today announced it has received a patent (US Patent No. 12,364,680) covering KIO-104 for the tr......
16.07.25 - 19:45
Kiora Pharmaceuticals (KPRX) Upgraded to Strong Buy: Here′s What You Should Know (Zacks)
 
Kiora Pharmaceuticals (KPRX) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term....
03.06.25 - 13:06
Kiora Pharmaceuticals, Inc.: Kiora Pharmaceuticals and Senju Pharmaceutical Partner on KIO-301 for the Treatment of Retinal Diseases in Asia (Newsfile)
 
Total potential deal value of $110 million plus royaltiesKiora to receive an immediate $1.25 million exclusive option feeIf the option is exercised, Kiora will receive an additional mid-single dig......
09.05.25 - 13:33
Kiora Pharmaceuticals GAAP EPS of -$0.52 (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
09.05.25 - 13:06
Kiora Pharmaceuticals, Inc.: Kiora Pharmaceuticals Reports First Quarter Results; Initiating Two Phase 2 Trials for Treatment of Retinal Diseases; Cash and Short-term Investments Expected to Fund Operations into Late 2027 (Newsfile)
 
Encinitas, California--(Newsfile Corp. - May 9, 2025) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") today announced first quarter 2025 financial results and provided an u......
05.05.25 - 13:12
Kiora Pharmaceuticals, Inc.: Kiora Pharmaceuticals Presents In Vivo Preclinical Data at ARVO 2025 Demonstrating the Potential of KIO-104 to Treat Proliferative Vitreoretinopathy (Newsfile)
 
Encinitas, California--(Newsfile Corp. - May 5, 2025) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), ("Kiora" or the "Company") today announced the results from a preclinical study demonstrating KI......
04.04.25 - 13:06
Kiora Pharmaceuticals, Inc.: Kiora Pharmaceuticals to Present at The 24th Annual Needham Virtual Healthcare Conference (Newsfile)
 
Ecinitas, California--(Newsfile Corp. - April 4, 2025) - Kiora Pharmaceuticals (NASDAQ: KPRX) invites investors to view the Company's online presentation at the 24th Annual Needham Virtual Healthc......
>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!
Zitat des Tages: Es gibt einen Tag, um geboren zu werden, und einen Tag, um zu sterben. - China Weisheit
>Aktien | >Anleihen | >ETFs | >Fonds | >Branchen | >Länder | >Themen | >Redaktionen
Partner:    >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook | Börsentreff auf X | Börsentreff auf Instagram

Copyright @ Boersentreff.de - Die Märkte im Blick!